Syndax Pharmaceuticals (SNDX) Price & Analysis

Compare

829 Followers

SNDX Stock Chart & Stats

$14.68

$0.12(0.87%)

At close: Jan 08 4:00 PM EST

$14.68

$0.12(0.87%)

Day’s Range― - ―

52-Week Range$8.58 - $22.50

Previous CloseN/A

Volume201.89K

Average Volume (3M)2.30M

Market Cap

$1.30B

Enterprise Value$698.84M

Total Cash (Recent Filing)$468.71M

Total Debt (Recent Filing)$1.68M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Nov 11, 2025

EPS Estimate

-0.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.83

Shares Outstanding86,141,860

10 Day Avg. Volume3,023,201

30 Day Avg. Volume2,302,510

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.54

Enterprise Value/Revenue8.94

Enterprise Value/Gross Profit9.29

Enterprise Value/Ebitda-2.18

Forecast

1Y Price Target

$34.00

Price Target Upside131.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Market PositionRevuforj is positioned to take the majority NPM1m market share over KURA given its physician familiarity and robust combination data.

Product LaunchRevuforj is now the best R/R AML commercial launch to date despite its eligibility for the smallest labeled patient subgroup.

Bears Say

Commercial ExecutionContinued commercial execution over quarterly reports is crucial for SNDX's stock, and management's success in this area could lead to a re-rating of the stock.

Market ValuationThe market continues to substantially undervalue SNDX with the stock trading at a deep discount vs. strong and only improving fundamentals.

Syndax Pharmaceuticals News

Syndax trading resumes

14:20 EDT Syndax (SNDX) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

22h ago

SNDX

Syndax confirms FDA approves second indication for Revuforj

Syndax (SNDX) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj for the treatment of...

22h ago

SNDX

$FDA approves Syndax’s revumenib for relapsed or refractory AML$

FDA approves Syndax’s revumenib for relapsed or refractory AML

The Food and Drug Administration approved revumenib, or Revuforj, from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed...

23h ago

SNDX

Syndax trading halted, news pending

12:56 EDT Syndax (SNDX) trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

24h ago

SNDX

Syndax assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Syndax (SNDX) with a Buy rating and $40 price target The firm has...

9d ago

SNDX

Syndax Pharmaceuticals Gains FDA Approval for Revuforj

The latest update is out from Syndax Pharmaceuticals ( ($SNDX) ). On October 24, 2025, Syndax Pharmaceuticals announced...

20h ago

SNDX

Strategic Positioning and Competitive Edge: Syndax Pharmaceuticals’ Buy Rating Reinforced by Revuforj’s Milestones in Leukemia Treatment

Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on SNDX stock, giving a Buy rating on...

1M ago

SNDX

Syndax announces updated NCCN Guidelines for AML

Syndax (SNDX) Pharmaceuticals announced that the National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology for Acute...

1M ago

SNDX

Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AME

BWA

3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

AVBP

NVDA

Syndax resumed with a Buy at Stifel

Stifel resumed coverage of Syndax (SNDX) with a Buy rating and $44 price target The firm believes the...

2M ago

SNDX

Optimistic Buy Rating for Syndax Pharmaceuticals Driven by Promising Market Position and Growth Potential

Syndax Pharmaceuticals (SNDX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Stephen Willey. Stephen Willey...

2M ago

SNDX

Syndax assumed with a Buy at Guggenheim

Guggenheim assumed coverage of Syndax (SNDX) with a Buy rating and price target of $34, up from $32....

2M ago

SNDX

Syndax assumed with a Buy at Guggenheim

Guggenheim assumed coverage of Syndax (SNDX) with a Buy rating and $34 price target Published first on TheFly...

2M ago

SNDX

SNDX FAQ

What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?

Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $22.50 in the past 12 months.

What is Syndax Pharmaceuticals Inc’s market cap?

Syndax Pharmaceuticals Inc’s market cap is $1.30B.

When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?

Syndax Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2025 which is in 17 days.

How were Syndax Pharmaceuticals Inc’s earnings last quarter?

Syndax Pharmaceuticals Inc released its earnings results on Aug 04, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.016 by $0.186.

Is Syndax Pharmaceuticals Inc overvalued?

According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Syndax Pharmaceuticals Inc pay dividends?

Syndax Pharmaceuticals Inc does not currently pay dividends.

What is Syndax Pharmaceuticals Inc’s EPS estimate?

Syndax Pharmaceuticals Inc’s EPS estimate is -0.73.

How many shares outstanding does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc has 86,141,860 shares outstanding.

What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?

Syndax Pharmaceuticals Inc reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.016. Following the earnings report the stock price went up 21.098%.

Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in SNDX

Syndax Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-113.22%

Trailing 12-Months

Asset Growth

24.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biotechnology sector, with a commitment to discovering, developing, and delivering novel therapies that address unmet needs in oncology. Its core products include a pipeline of drug candidates designed to enhance the effectiveness of existing cancer treatments and improve patient outcomes.

Syndax Pharmaceuticals (SNDX) Earnings & Revenues

Historic Earnings Reports

SNDX Company Deck

SNDX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance with significant revenue growth and strategic advancements in pipeline and market expansion. The company shows a clear path to profitability with stable operating expenses and promising future opportunities. However, there are some dependencies on regulatory approvals and expectations for increased transplant rates.View all SNDX earnings summaries

SNDX Stock 12 Month Forecast

Average Price Target

$34.00

▲(131.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","57":"$57","19.5":"$19.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.5,32,44.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,18.78153846153846,21.88307692307692,24.984615384615385,28.086153846153845,31.187692307692306,34.28923076923077,37.39076923076923,40.49230769230769,43.59384615384615,46.69538461538461,49.79692307692307,52.89846153846154,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,17.08923076923077,18.498461538461537,19.907692307692308,21.316923076923075,22.726153846153846,24.135384615384616,25.544615384615383,26.953846153846154,28.363076923076925,29.77230769230769,31.181538461538462,32.59076923076923,{"y":34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,15.781538461538462,15.883076923076922,15.984615384615385,16.086153846153845,16.18769230769231,16.28923076923077,16.39076923076923,16.49230769230769,16.593846153846155,16.695384615384615,16.796923076923076,16.89846153846154,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.89,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >